Rectal administration of feprazone in healthy volunteers.
作者信息
Ferrari P, Montanari C, Sala P, Vidi A
出版信息
Br J Clin Pharmacol. 1976 Apr;3(2):339-40. doi: 10.1111/j.1365-2125.1976.tb00616.x.
Abstract
摘要
相似文献
1
Rectal administration of feprazone in healthy volunteers.在健康志愿者中进行非普拉宗的直肠给药。
Br J Clin Pharmacol. 1976 Apr;3(2):339-40. doi: 10.1111/j.1365-2125.1976.tb00616.x.
2
The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study.氢氧化铝对非普拉宗生物利用度的影响。单剂量研究。
Arzneimittelforschung. 1985;35(1):167-9.
3
High-pressure liquid chromatographic feprazone determination in pharmaceutical formulations.药物制剂中非普拉宗的高效液相色谱测定法
J Pharm Sci. 1979 Jun;68(6):798-800. doi: 10.1002/jps.2600680638.
4
Inducing effect of feprazone on hepatic drug-metabolizing enzymes in man.非普拉宗对人体肝脏药物代谢酶的诱导作用。
Eur J Clin Pharmacol. 1986;31(1):117-8. doi: 10.1007/BF00870999.
5
A trial of feprazone in ankylosing spondylitis.非普拉宗治疗强直性脊柱炎的试验。
Rheumatol Rehabil. 1977 Aug;16(3):158-61. doi: 10.1093/rheumatology/16.3.158.
6
[Gas chromatographic determination of Feprazone in medicinal preparations].[气相色谱法测定药物制剂中的非普拉宗]
Farmaco Prat. 1975 Mar;30(3):147-52.
7
[Topical treatment of thrombophlebitis with feprazone and benzydamine. Controlled clinical study].[用非普拉宗和苄达明局部治疗血栓性静脉炎。对照临床研究]
Minerva Med. 1976 Mar 24;67(14):880-4.
8
Gastrointestinal blood loss on phenylbutazone and feprazone.保泰松和非普拉宗引起的胃肠道失血。
Rheumatol Rehabil. 1976 May;15(2):108-11. doi: 10.1093/rheumatology/15.2.108.
9
Gas-chromatographic analysis of 4-prenyl-1,2-diphenyl-3-5-pyrazolidinedione (feprazone) at therapeutic levles in human plasma.人血浆中治疗浓度的4-异戊烯基-1,2-二苯基-3,5-吡唑烷二酮（非普拉宗）的气相色谱分析
J Chromatogr. 1975 Nov 12;114(1):159-65. doi: 10.1016/s0021-9673(00)85252-8.
10
Double-blind trial of feprazone and phenylbutazone in acute gout.非普拉宗与保泰松治疗急性痛风的双盲试验。
Curr Med Res Opin. 1980;6(7):445-8. doi: 10.1185/03007998009109465.
本文引用的文献
1
Physico-chemical and analytical studies on 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).4-异戊烯基-1,2-二苯基-3,5-吡唑烷二酮（DA 2370）的物理化学与分析研究
Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:177+.
2
The use of balanced incomplete block designs in comparative bioavailability trails.平衡不完全区组设计在比较生物利用度试验中的应用。
Biometrics. 1974 Jun;30(2):319-27.
3
Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.4-异戊烯基-1,2-二苯基-3,5-吡唑烷二酮（DA 2370）用于类风湿性关节炎和强直性脊柱炎的临床及实验室评估
Arzneimittelforschung. 1972 Jan;22(1):Suppl 1a:253-8.
4
Feprazone compared with indomethacin in the management of rheumatoid arthritis.联苯乙酸与吲哚美辛治疗类风湿关节炎的比较。
Practitioner. 1975 Jul;215(1285):94-7.
5
A double-blind cross-over trail of Prenazone and aspirin in the management of rheumatoid arthritis.
Rheumatol Rehabil. 1975 May;14(2):61-70. doi: 10.1093/rheumatology/14.2.61.
6
Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.非普拉宗，一种新型抗炎药。效能及胃肠道耐受性研究。
Ann Rheum Dis. 1975 Apr;34(2):190-4. doi: 10.1136/ard.34.2.190.
Zotero 插件